Dr Peter Szlosarek

Barts Cancer Institute
Queen Mary University of London

Research Interests

My main research areas are in Lung cancer, Mesothelioma and Melanoma, Cancer metabolism, Epigenetics, Immunity and Inflammation and Clinical Trials.

My research group focuses on:

- Abnormal metabolic circuits in cancer development and treatment.
- Novel cancer genes involved in inflammation and immunity
- Cancer epigenetics as applied to thoracic cancers and melanoma
- Translational research from bench to bedside and back again with an emphasis on new biomarkers
- I am a chief and principal investigator of novel targeted anticancer drugs, including modulators of metabolism and immune/inflammatory pathways in thoracic cancers and melanoma.

Major Funders

- Cancer Research UK
- Medical Research Council
- British Lung Foundation
- Mick Knighton Mesothelioma Research Fund
- June Hancock Mesothelioma Research Fund
- Barts and The London Charity

Contact Details

Email: p.w.szlosarek@qmul.ac.uk

Dr Peter Szlosarek

Barts Cancer Institute
Queen Mary University of London

Recent Publications

- Prognostic and therapeutic impact of argininosuccinate synthetase-1 control in bladder cancer as monitored longitudinally by PET imaging. Allen M, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu B-W, Bomalaski JS, Jackson RC, Lu Y-J, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li C-F, **Szlosarek PW**. *Cancer Res,* in press.

- Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Phillips MM, Sheaff MT, **Szlosarek PW**. *Cancer Res Treat*, in press.

- **Szlosarek PW**, Luong P, Phillips P, Baccarini M, Ellis S, Szyszko T, Sheaff MT, Avril N. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. *J Clin Oncol* 2013; 31:e111-3.

- Zhang L, MacKenzie ED, Karim SA, Kalna G, Watson DG, **Szlosarek P,** Frezza, C, Gottlieb E. Reversed urea cycle activity in fumarate hydratase-deficient cancer cells. *Cancer & Metabolism* 2013; 1:12.

- Delage B, Luong P, Lenushka M, O'Riain C, Syed N, Crook T, Hatzimichael, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R, Calaminici M, Gribben J, Lemoine NR, Bomalaski J, Li CF, Joel S, Fitzgibbon J, Chen LT, **Szlosarek PW**. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. *Cell Death Dis* 2012; 3:e342.

- Delage B, Fennell DA, Nicholson LJ, McNeish IA, Lemoine NR, Crook T, **Szlosarek PW**. Arginine deprivation and argininosuccinate synthetase expression for the treatment of human cancer. Int J Cancer 2010; 126:2762-72.